Skip to content
10-Q

Quarterly Report

BioCrude Technologies USA, Inc.

0001731122-26-000715

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 50.87M sh
Stock Issued Q1 2026 · Mar 31, 2026 5.5K sh
Shares Diluted Q1 2026 · Mar 31, 2026 50.76M sh
Shares Diluted Q1 2026 · Mar 31, 2025 50.8M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$13.37K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$30.13K
Short Term Debt Q1 2026 · Mar 31, 2026 $158.25K
Short Term Debt Q1 2026 · Dec 31, 2025 $137.24K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$465.66K
Stockholders Equity Q1 2026 · Dec 31, 2025 −$467.45K
Current Liabilities Q1 2026 · Mar 31, 2026 $494.24K
Current Liabilities Q1 2026 · Dec 31, 2025 $482.43K
Total Liabilities Q1 2026 · Mar 31, 2026 $494.24K
Total Liabilities Q1 2026 · Dec 31, 2025 $482.43K
Current Assets Q1 2026 · Mar 31, 2026 $16.79K
Current Assets Q1 2026 · Dec 31, 2025 $1.95K
Total Assets Q1 2026 · Mar 31, 2026 $24.61K
Total Assets Q1 2026 · Dec 31, 2025 $10.98K
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $34.43K
Sga Expense Q1 2026 · Mar 31, 2025 $57.74K
Net Income Q1 2026 · Mar 31, 2026 −$35.29K
Net Income Q1 2026 · Mar 31, 2025 −$58.65K
Operating Income Q1 2026 · Mar 31, 2026 −$34.43K
Operating Income Q1 2026 · Mar 31, 2025 −$57.74K